Viking Therapeutics (VKTX) Notes Payables (2014 - 2018)

Viking Therapeutics (VKTX) posted Notes Payables of $3.7 million for Q1 2018, up 7.82% sequentially from $3.5 million in Q4 2017.

Viking Therapeutics (VKTX) Notes Payables (2014 - 2018) Analysis & Trends

Viking Therapeutics has reported Notes Payables for 5 years, with the latest figure at $3.7 million in Q1 2018.

Quarterly Notes Payables changed N/A year-over-year to $3.7 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $3.7 million (changed N/A YoY) and the FY2017 annual result came in at $3.5 million, up 5.55% from the prior year.
Notes Payables climbed to $3.7 million in Q1 2018 per VKTX's latest filing, from $3.5 million in the prior quarter.
Over five years, Notes Payables peaked at $3.7 million in Q1 2018 and troughed at $304274.0 in Q4 2014.
A 5-year average of $2.4 million and a median of $2.8 million in 2016 frame the typical range for Notes Payables.
The sharpest annual moves came in 2016 and 2017: Notes Payables jumped 47.89% in 2016, then gained 5.55% in 2017.
Over 5 years, Notes Payables stood at $304274.0 in 2014, then soared by 528.06% to $1.9 million in 2015, then surged by 71.09% to $3.3 million in 2016, then grew by 5.55% to $3.5 million in 2017, then grew by 7.82% to $3.7 million in 2018.
According to Business Quant data, Notes Payables over the past three periods registered $3.7 million, $3.5 million, and $3.2 million for Q1 2018, Q4 2017, and Q3 2017 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Viking Therapeutics	3.87 Bn	3.87 Bn	-

Download Data